Business continues to grow at a sustained pace in the first half of 2021 – Two highly impactful announcements for iBiopsy® and iCRO business units during Q3, 2021 -Third quarter revenue of €5.3m, up by 51% on the third quarter of 2020 – Cash and cash equivalents of €42.6m as of September 30th, 2021
Read moreMedian Technologies (ALMDT:PA) announced today that Fredrik Brag, CEO and founder of Median Technologies, will provide a company update on October 25th, 2021 at 6:00 pm CEST during a webcast.
Read moreThis is the result of the renegotiation of terms of an existing Master Service Agreement (MSA) with this major big pharmaceutical company. The new scope of the MSA covers Phase III clinical trials for major indications in oncology and the terms are valid for 3 years. This partnership will contribute to sustain Median’s future bookings and revenues growth.
Read moreMedian Technologies announces outstanding performance for its iBiopsy® Lung Cancer Screening CADx[1] to accurately characterize malignant vs benign lung nodules based on a large-scale patient cohort. Results show cutting-edge performance of 95.2% sensitivity and 95.7% specificity for lung nodule characterization that could significantly impact lung cancer screening programs adoption. The large-scale study is based on a cohort of 1,696 patients with a total of 15,608 lung nodules. Further results on a fully automated end-to-end lung cancer screening CADe/CADx including nodule detection and characterizationre expected in Q4, 2021.
Read moreTo download this content please complete the form below
[contact-form-7 id="5108" title="Download file form"]